Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and mechanistic literature with no new clinical data or clinical trials
PubMed 41008588 · doi:10.3390/biom15091281
What was done
This narrative review summarizes literature regarding the mechanistic role of nicotinamide N-methyltransferase (NNMT) and its metabolite 1-methylnicotinamide (1-MNA) in cardiovascular disease (CVD) pathogenesis, cardiometabolic risk factors (obesity, diabetes, hypertension, hyperlipidemia), and preclinical therapeutic modulation (small-molecule inhibitors and RNA interference).
What was found
The abstract reports no numerical data. Mechanistically, NNMT enzymatic activity consumes nicotinamide and S-adenosylmethionine, causing NAD+ depletion, impaired mitochondrial and sirtuin (SIRT1/SIRT3) activity, elevated homocysteine, and activation of pro-inflammatory cascades (TLR4-NF-κB, STAT3-IL-1β). Conversely, 1-MNA demonstrates protective effects through NRF2 activation and antithrombotic mechanisms. In preclinical animal models, NNMT inhibition or knockdown improved insulin sensitivity, reduced atherosclerosis, and attenuated cardiac dysfunction.
Why it matters
NNMT functions at the intersection of cellular methylation and NAD+ metabolism, providing insight into metabolic drivers of atherosclerosis and serving as a potential cardiometabolic drug target.
Limits
The review relies entirely on preclinical and mechanistic findings; no human clinical trials targeting NNMT in cardiovascular disease have been conducted. The abstract provides no quantitative effect sizes or study counts, and the balance between the pathogenic effects of NNMT and the protective actions of 1-MNA across specific tissues remains unresolved.
Cited by
- supports 1-Methylnicotinamide (1-MNA) is the breakdown clearance byproduct of NAD metabolism.